The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies

Virology

Volumn 408, Issue 2, 2010, Pages 213-223

  Peachman, Kristina K ^a,b   Wieczorek, Lindsay ^a,b   Polonis, Victoria R ^b   Alving, Carl R ^b   Rao, Mangala ^b  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Gp41; HIV 1; Monoclonal antibodies; Neutralization; Soluble CD4; Surface plasmon resonance; Virus capture

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; SOLUBLE CD4 ANTIGEN;

ANTIGEN BINDING; ARTICLE; CELL STRAIN HEK293; CLADISTICS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN CONTENT; PROTEIN TARGETING; SURFACE PLASMON RESONANCE; VIRION; VIRUS ATTACHMENT; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; EPITOPES; GENES, VIRAL; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MUTATION; PEPTIDE FRAGMENTS; SOLUBILITY; SURFACE PLASMON RESONANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78149409816     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.09.029     Document Type: Article

References (50)

1. Alam S.M., Morelli M., Dennison S.M., Liao H.X., Zhang R., Xia S.M., Rits-Volloch S., Sun L., Harrison S.C., Haynes B.F., Chen B. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl Acad. Sci. USA 2009, 106(48):20234-20239.
2. Alving C.R., Beck Z., Karasavva N., Matyas G.R., Rao M. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies. Mol. Membr. Biol. 2006, 23(6):453-465.
3. Berger E.A., Murphy P.M., Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17:657-700.
4. Binley J.M., Cayanan C.S., Wiley C., Schülke N., Olson W.C., Burton D.R. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 2003, 77(10):5678-5684.
5. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78(23):13232-13252.
6. Bjorck L., Kronvall J. Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. J. Immunol. 1984, 133(2):969-974.
7. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., de Souza M.S., Birx D.L., McCutchan F.E., Polonis V.R. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 2005, 79(10):6089-6101.
8. Brown B.K., Karasavvas N., Beck Z., Matyas G.R., Birx D.L., Polonis V.R., Alving C.R. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J. Virol. 2007, 81(4):2087-2091.
9. Brown B.K., Wieczorek L., Sanders-Buell E., Rosa Borges A., Robb M.L., Birx D.L., Michael N.L., McCutchan F.E., Polonis V.R. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008, 375(2):529-538.
10. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5(3):233-236.
11. Burton D.R., Stanfield R.L., Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 2005, 102(42):14943-14948.
12. Cardozo T., Kimura T., Philpott S., Weiser B., Burger H., Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1V3 loop. AIDS Res. Hum. Retroviruses 2007, 23(3):415-426.
13. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93(5):681-684.
14. Colman P.M., Lawrence M.C. The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 2003, 4(4):309-319.
15. Crooks E.T., Moore P.L., Richman D., Robinson J., Crooks J.A., Franti M., Schülke N., Binley J.M. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antibodies 2005, 14(3-4):101-113.
16. de Rosny E., Vassell R., Jiang S., Kunert R., Weiss C.D. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J. Virol. 2004, 78(5):2627-2631.
17. Doms R.W. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 2000, 276(2):229-237.
18. Frey G., Peng H., Rits-Volloch S., Morelli M., Cheng Y., Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl Acad. Sci. USA 2008, 105(10):3739-3744.
19. Gorny M.K., Gianakakos V., Sharpe S., Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc. Natl Acad. Sci. USA 1989, 86(5):1624-1628.
20. Haim H., Si Z., Madani N., Wang L., Courter J.R., Princiotto A., Kassa A., DeGrace M., McGee-Estrada K., Mefford M., Gabuzda D., Smith A.B., Sodroski J. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 2009, 5(4):e1000360.
21. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008, 15(7):690-698.
22. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308(5730):1906-1908.
23. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310(5750):1025-1028.
24. Leaman D.P., Kinkead H., Zwick M.B. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 2010, 84(4):3382-3395.
25. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79(17):10108-10125.
26. Louder M.K., Sambor A., Chertova E., Hunte T., Barrett S., Ojong F., Sanders-Buell E., Zolla-Pazner S., McCutchan F.E., Roser J.D., Gabuzda D., Lifson J.D., Mascola J.R. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 2005, 339(2):226-238.
27. Lusso P., Earl P.L., Sironi F., Santoro F., Ripamonti C., Scarlatti G., Longhi R., Berger E.A., Burastero S.E. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J. Virol. 2005, 79(11):6957-6968.
28. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 2005, 79(16):10103-10107.
29. Matyas G.R., Beck Z., Karasavvas N., Alving C.R. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta 2009, 1788(3):660-665.
30. Matyas G.R., Wieczorek L., Beck Z., Ochsenbauer-Jambor C., Kappes J.C., Michael N.L., Polonis V.R., Alving C.R. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009, 23(16):2069-2077.
31. Mbah H.A., Burda S., Gorny M.K., Williams C., Revesz K., Zolla-Pazner S., Nyambi P.N. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J. Virol. 2001, 75(16):7785-7788.
32. Moody M.A., Liao H., Alam S.M., Scearce R.M., Plonk M.K., Kozink D.M., Drinker M.S., Zhang R., Xia S., Sutherland L.L., Tomaras G.D., Giles I.P., Kappes J.C., Ochsenbauer-Jambor C., Edmonds T.G., Soares M., Barbero G., Forthal D.N., Landucci G., Chang C., King S.W., Kavlie A., Denny T.N., Hwang K., Chen P.P., Thorpe P.E., Montefiori D.C., Haynes B.F. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines. JEM 2010, 207(4):763-776.
33. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., Corcoran P., Zwick M.B., Franti M., Morris L., Roux K.H., Burton D.R., Binley J.M. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 2006, 80(5):2515-2528.
34. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67(11):6642-6647.
35. Nyambi P.N., Mbah H.A., Burda S., Williams C., Gorny M.K., Nádas A., Zolla-Pazner S. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J. Virol. 2000, 74(7):7096-7107.
36. Nyambi P.N., Gorny M.K., Bastiani L., van der Groen G., Williams C., Zolla-Pazner S. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 1998, 72(11):9384-9391.
37. Nyambi P.N., Burda S., Bastiani L., Williams C. A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1. J. Immunol. Methods 2001, 253(1-2):253-262.
38. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 2004, 78(10):5205-5215.
39. Poignard P., Moulard M., Golez E., Vivona V., Franti M., Venturini S., Wang M., Parren P.W., Burton D.R. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 2003, 77(1):353-365.
40. Rossio J.L., Esser M.T., Suryanarayana K., Schneider D.K., Bess J.W., Vasquez G.M., Wiltrout T.A., Chertova E., Grimes M.K., Sattentau Q., Arthur L.O., Henderson L.E., Lifson J.D. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 1998, 72(10):7992-8001.
41. Rutebemberwa A., Bess J.W., Brown B., Arroyo M., Eller M., Slike B., Polonis V., McCutchan F., Currier J.R., Birx D., Robb M., Marovich M., Lifson J.D., Cox J.H. Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses. AIDS Res. Hum. Retroviruses 2007, 23(4):532-542.
42. Sánchez-Martínez S., Lorizate M., Hermann K., Kunert R., Basañez G., Nieva J.L. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 2006, 580(9):2395-2399.
43. Stanfield R.L., Gorny M.K., Zolla-Pazner S., Wilson I.A. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 2006, 80(12):6093-6105.
44. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289. G. Protocol G Principal Investigators.
45. Wu X., Sambor A., Nason M.C., Yang Z.Y., Wu L., Zolla-Pazner S., Nabel G.J., Mascola J.R. Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology 2008, 380(2):285-295.
46. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280(5371):1884-1888.
47. Xu H., Song L., Kim M., Holmes M.A., Kraft Z., Sellhorn G., Reinherz E.L., Stamatatos L., Strong R.K. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J. Virol. 2010, 84(2):1076-1088.
48. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445(7129):732-737.
49. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75(22):10892-10905.
50. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004, 4(3):199-210.